With promising in vitro data utilizing ASOs to boost NF1 expression, iNFixon launches seed financing round to fund in vivo animal studies

iNFixion Bioscience is developing an antisense oligonucleotide (ASO) therapy designed to boost NF1 protein expression, aiming to address the underlying root cause driver of neurofibromatosis type 1 (NF1) symptoms, namely NF1 protein haploinsufficiency. Following promising in vitro data, demonstrating the potential for this approach across multiple human cell types, the company has launched a seed financing round to advance in vivo rodent studies. This funding will support crucial preclinical research to further validate the therapy’s safety and efficacy, and to move it one step closer to the clinic for NF1 patients.